Chi Shang Tai

Director/Board Member at ZICOM GROUP LIMITED

46 year

Health Technology

Producer Manufacturing

Consumer Services

Profile

Chi Shang Tai is the founder of Histoindex Pte Ltd.
He currently holds a position as a Non-Independent Non-Executive Director at Zicom Group Ltd.
Dr. Tai has an undergraduate and doctorate degree from Auckland University.

Chi Shang Tai active positions

Companies	Position	Start
ZICOM GROUP LIMITED	Director/Board Member	2020-11-29
Histoindex Pte Ltd. Histoindex Pte Ltd. Medical SpecialtiesHealth Technology Histoindex Pte Ltd. is a medtech/healthcare company based in Singapore, Singapore. The stain-free AI platform is currently involved in multiple FDA clinical trials for nonalcoholic steatohepatitis (NASH) and has benefitted more than 150 research and academic institutes, CROs, and biopharma companies worldwide in drug discovery and development efforts for fibrotic diseases and cancers. Founded in 2010, the Singaporean company specializes in its proprietary integrated stain-free AI digital pathology platform that accurately quantifies histological features and fine measurements critical for the evaluation of therapeutic efficacy in clinical trials. The company was founded by Gideon Ho, Chi-Shang Tai, and Gideon Ho has been the CEO since incorporation.	Founder	2010-03-31

All active positions of Chi Shang Tai

Training of Chi Shang Tai

Auckland University

Doctorate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Chi Shang Tai's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	1
ZICOM GROUP LIMITED	Producer Manufacturing

Private companies	1
Histoindex Pte Ltd. Histoindex Pte Ltd. Medical SpecialtiesHealth Technology Histoindex Pte Ltd. is a medtech/healthcare company based in Singapore, Singapore. The stain-free AI platform is currently involved in multiple FDA clinical trials for nonalcoholic steatohepatitis (NASH) and has benefitted more than 150 research and academic institutes, CROs, and biopharma companies worldwide in drug discovery and development efforts for fibrotic diseases and cancers. Founded in 2010, the Singaporean company specializes in its proprietary integrated stain-free AI digital pathology platform that accurately quantifies histological features and fine measurements critical for the evaluation of therapeutic efficacy in clinical trials. The company was founded by Gideon Ho, Chi-Shang Tai, and Gideon Ho has been the CEO since incorporation.	Health Technology